JP2020512019A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512019A5 JP2020512019A5 JP2020503358A JP2020503358A JP2020512019A5 JP 2020512019 A5 JP2020512019 A5 JP 2020512019A5 JP 2020503358 A JP2020503358 A JP 2020503358A JP 2020503358 A JP2020503358 A JP 2020503358A JP 2020512019 A5 JP2020512019 A5 JP 2020512019A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- gene
- ucart
- seq
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023114120A JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770239 | 2017-03-31 | ||
| DKPA201770239 | 2017-03-31 | ||
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770542 | 2017-06-30 | ||
| DKPA201770542 | 2017-06-30 | ||
| PCT/EP2017/076800 WO2018073393A2 (en) | 2016-10-19 | 2017-10-19 | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| EPPCT/EP2017/076800 | 2017-10-19 | ||
| PCT/EP2018/058367 WO2018178377A1 (en) | 2017-03-31 | 2018-03-30 | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114120A Division JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512019A JP2020512019A (ja) | 2020-04-23 |
| JP2020512019A5 true JP2020512019A5 (https=) | 2021-05-06 |
| JP7314115B2 JP7314115B2 (ja) | 2023-07-25 |
Family
ID=63674321
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503358A Active JP7314115B2 (ja) | 2017-03-31 | 2018-03-30 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
| JP2023114120A Active JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023114120A Active JP7634045B2 (ja) | 2017-03-31 | 2023-07-12 | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11690873B2 (https=) |
| EP (3) | EP4414380A3 (https=) |
| JP (2) | JP7314115B2 (https=) |
| KR (1) | KR102726269B1 (https=) |
| CN (1) | CN110869046B (https=) |
| AU (2) | AU2018246377B2 (https=) |
| BR (1) | BR112019020203A2 (https=) |
| CA (1) | CA3058268A1 (https=) |
| DK (1) | DK3592379T3 (https=) |
| ES (1) | ES2979232T3 (https=) |
| IL (1) | IL269538B2 (https=) |
| MX (1) | MX2019011475A (https=) |
| PT (1) | PT3592379T (https=) |
| WO (2) | WO2018178377A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109415687A (zh) * | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| EP3523296A4 (en) | 2016-10-05 | 2020-04-01 | The Board of Trustees of the Leland Stanford Junior University | BRYOSTATIN COMPOUNDS AND METHOD FOR PRODUCING THE SAME |
| EP4414380A3 (en) * | 2017-03-31 | 2024-12-04 | Cellectis SA | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| BR112020006643A2 (pt) | 2017-10-03 | 2020-09-24 | Juno Therapeutics Inc | moléculas de ligação específica ao hpv |
| CN112888709B (zh) * | 2018-03-30 | 2024-10-29 | 优瑞科生物技术公司 | 标靶cd22的构建体和其用途 |
| CA3094468A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| WO2020132327A1 (en) * | 2018-12-19 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
| JP7664180B2 (ja) * | 2019-04-26 | 2025-04-17 | アロジーン セラピューティクス，インコーポレイテッド | リツキシマブ耐性キメラ抗原受容体およびその用途 |
| CA3140621A1 (en) * | 2019-05-21 | 2020-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin compounds for enhancement of immunotherapy |
| EP4127188A4 (en) * | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| CN113527507A (zh) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| GB202007842D0 (en) * | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| JP7766674B2 (ja) * | 2020-07-31 | 2025-11-10 | セレクティス ソシエテ アノニム | 二重ｃａｒ－ｔ細胞 |
| CN111944850B (zh) * | 2020-08-28 | 2023-03-31 | 澳门大学 | 表达抗cd22嵌合抗原受体和pd-l1阻断蛋白的细胞的制备方法、表达载体及应用 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| EP4294831A1 (en) * | 2021-02-16 | 2023-12-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class i-restricted t cell receptors against cd22 |
| KR102829757B1 (ko) * | 2021-11-17 | 2025-07-09 | (주)이노베이션바이오 | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 |
| US20250059569A1 (en) * | 2021-12-22 | 2025-02-20 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for delivery of therapeutic agents to acceptor cells |
| EP4653467A1 (en) * | 2023-01-19 | 2025-11-26 | Wuhan Zhaozhi Biotechnology Co., Ltd. | Car molecule, cell or exosome containing same, and use thereof |
| WO2025049961A1 (en) * | 2023-09-01 | 2025-03-06 | Cargo Therapeutics, Inc. | Anti-cd22 chimeric antigen receptor (car) therapies |
| WO2025212803A2 (en) * | 2024-04-03 | 2025-10-09 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd22 chimeric antigen receptors |
| CN119775433B (zh) * | 2024-12-09 | 2025-11-28 | 吉林大学第一医院 | 一种细胞膜表达的il-15融合蛋白及其在细胞治疗中的应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| WO1997034598A1 (en) | 1996-03-20 | 1997-09-25 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of treating cancer using c-26 modified bryostatin |
| AU744445B2 (en) | 1997-04-24 | 2002-02-21 | University Of Washington | Targeted gene modification by parvoviral vectors |
| WO2001040214A1 (en) | 1999-11-30 | 2001-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| WO2008100450A2 (en) | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| PH12016502073B1 (en) * | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| EP2694089B1 (en) | 2011-04-05 | 2024-06-05 | Cellectis | New tale-protein scaffolds and uses thereof |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126720A2 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| CN104769103B (zh) | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | 多链嵌合抗原受体和其用途 |
| CN104822705B (zh) | 2012-10-24 | 2019-07-12 | 美国卫生和人力服务部 | M971嵌合抗原受体 |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| KR102348577B1 (ko) * | 2013-11-22 | 2022-01-06 | 셀렉티스 | 면역요법을 위한 화학요법 약물 저항성 ｔ―세포들의 조작 방법 |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| MX373460B (es) * | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| CA2943008C (en) * | 2014-03-19 | 2021-03-30 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
| WO2015158671A1 (en) * | 2014-04-14 | 2015-10-22 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| ES2869972T3 (es) * | 2015-01-26 | 2021-10-26 | Cellectis | Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas |
| WO2016124765A1 (en) * | 2015-02-06 | 2016-08-11 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| US10738116B2 (en) | 2015-03-19 | 2020-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors |
| KR20260048600A (ko) * | 2015-03-27 | 2026-04-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 변형된 t 세포 및 이의 제조 및 사용 방법 |
| EP3307887A1 (en) | 2015-06-09 | 2018-04-18 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for improving transplantation |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| CN105958210B (zh) | 2016-05-06 | 2018-10-30 | 中国科学院国家天文台 | Fast望远镜开孔式反射面单元及其开孔方法 |
| CN105968210B (zh) * | 2016-05-13 | 2019-05-31 | 深圳生创精准医疗科技有限公司 | 靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途 |
| JP7195154B2 (ja) | 2016-07-06 | 2022-12-23 | セレクティス | 初代免疫細胞における逐次遺伝子編集 |
| WO2018073394A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| WO2018073391A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| WO2018073393A2 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| EP4414380A3 (en) | 2017-03-31 | 2024-12-04 | Cellectis SA | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| US12144825B2 (en) * | 2017-06-30 | 2024-11-19 | Cellectis | Cellular immunotherapy for repetitive administration |
| US20230248825A1 (en) * | 2020-07-24 | 2023-08-10 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
-
2018
- 2018-03-30 EP EP24166930.8A patent/EP4414380A3/en active Pending
- 2018-03-30 WO PCT/EP2018/058367 patent/WO2018178377A1/en not_active Ceased
- 2018-03-30 AU AU2018246377A patent/AU2018246377B2/en active Active
- 2018-03-30 ES ES18715024T patent/ES2979232T3/es active Active
- 2018-03-30 AU AU2018246378A patent/AU2018246378A1/en not_active Abandoned
- 2018-03-30 WO PCT/EP2018/058368 patent/WO2018178378A1/en not_active Ceased
- 2018-03-30 PT PT187150248T patent/PT3592379T/pt unknown
- 2018-03-30 MX MX2019011475A patent/MX2019011475A/es unknown
- 2018-03-30 EP EP18715024.8A patent/EP3592379B1/en active Active
- 2018-03-30 KR KR1020197032371A patent/KR102726269B1/ko active Active
- 2018-03-30 JP JP2020503358A patent/JP7314115B2/ja active Active
- 2018-03-30 CA CA3058268A patent/CA3058268A1/en active Pending
- 2018-03-30 DK DK18715024.8T patent/DK3592379T3/da active
- 2018-03-30 US US16/498,276 patent/US11690873B2/en active Active
- 2018-03-30 EP EP18715025.5A patent/EP3592380B1/en active Active
- 2018-03-30 BR BR112019020203-0A patent/BR112019020203A2/pt unknown
- 2018-03-30 CN CN201880036267.2A patent/CN110869046B/zh active Active
- 2018-03-30 US US16/498,899 patent/US11944643B2/en active Active
-
2019
- 2019-09-23 IL IL269538A patent/IL269538B2/en unknown
-
2023
- 2023-07-12 JP JP2023114120A patent/JP7634045B2/ja active Active
- 2023-12-21 US US18/393,322 patent/US12133867B2/en active Active
-
2024
- 2024-09-26 US US18/898,069 patent/US20250026808A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512019A5 (https=) | ||
| JP7157839B2 (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
| JP2023139070A5 (https=) | ||
| CN107109421B (zh) | Car表达载体及car表达t细胞 | |
| JP2024105296A5 (https=) | ||
| JP2021531004A5 (https=) | ||
| JP2019511222A5 (https=) | ||
| CN104853765A (zh) | 肿瘤特异性t细胞受体 | |
| JP2015527070A5 (https=) | ||
| CN106536563A (zh) | 嵌合抗原受体 | |
| JP7012364B2 (ja) | Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断 | |
| TW202102533A (zh) | Ｔ細胞受體及其使用方法 | |
| EP4502150A1 (en) | Engineered immune cell with cd7 gene knock-out and use thereof | |
| JP2021501567A (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞−抗原カプラおよびその方法ならびに使用 | |
| JP7747724B2 (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 | |
| CN113195535A (zh) | 用于连接表达car的免疫细胞与抗原呈递细胞的双特异性多肽及其用途 | |
| WO2021223604A1 (zh) | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 | |
| WO2023207390A1 (zh) | 一种ciita基因被敲除的工程化免疫细胞及其用途 | |
| JP2018518945A (ja) | 可溶性キメラインターロイキン−１０受容体およびその療法使用 | |
| WO2021190550A1 (zh) | 含有保护肽的嵌合抗原受体及其用途 | |
| CN114555815A (zh) | T细胞受体及其使用方法 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| TWI881993B (zh) | Ｔ細胞受體及其使用方法 | |
| TWI869426B (zh) | Ｔ細胞受體及其使用方法 | |
| CN111499766A (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 |